{"analyses":[{"ciLowerLimit":"5.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"19.14","groupDescription":"6-month survival","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","pValueComment":"The p-value for the difference in survival rate was derived from the z-test using the standard errors computed using Greenwood's method.","paramType":"Difference in Survival Percentage","paramValue":"12.4","statisticalMethod":"z-test","testedNonInferiority":false},{"ciLowerLimit":"2.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"19.33","groupDescription":"1-year survival","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0104","pValueComment":"The p-value for the difference in survival rates was derived from the z-test using the standard errors computed using Greenwood's method.","paramType":"Difference in Survival Percentage","paramValue":"11.0","statisticalMethod":"z-test","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.52","upperLimit":"94.11","value":"91.3"},{"groupId":"OG001","lowerLimit":"72.78","upperLimit":"85.04","value":"78.9"}]}],"title":"6-Month Survival"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.23","upperLimit":"80.79","value":"76.5"},{"groupId":"OG001","lowerLimit":"58.36","upperLimit":"72.76","value":"65.6"}]}],"title":"1-Year Survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"404"},{"groupId":"OG001","value":"198"}],"units":"Participants"}],"description":"6-month and 1-year survival were defined as the percentage of participants who were alive at 6 months and 1 year, respectively, as estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.","id":"OG000","title":"Trastuzumab Emtansine"},{"description":"Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.","id":"OG001","title":"Treatment of Physician's Choice"}],"paramType":"NUMBER","populationDescription":"Randomized population: All participants who were randomized to the study. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline to the clinical cut-off date of 13 Feb 2015 (up to 4 years)","title":"6-month and 1-year Survival (Final Analysis)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}